vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Waters Corporation (WAT). Click either name above to swap in a different company.

Waters Corporation is the larger business by last-quarter revenue ($932.4M vs $62.1M, roughly 15.0× Cytek Biosciences, Inc.). Waters Corporation runs the higher net margin — 24.2% vs -70.9%, a 95.1% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 6.8%). Over the past eight quarters, Waters Corporation's revenue compounded faster (21.0% CAGR vs 17.7%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Waters Corporation is an American company headquartered in Milford, Massachusetts that provides analytical instruments and software used for chromatography, mass spectrometry, laboratory informatics, and rheometry by the life sciences, materials, and food industries.

CTKB vs WAT — Head-to-Head

Bigger by revenue
WAT
WAT
15.0× larger
WAT
$932.4M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+1.3% gap
CTKB
8.1%
6.8%
WAT
Higher net margin
WAT
WAT
95.1% more per $
WAT
24.2%
-70.9%
CTKB
Faster 2-yr revenue CAGR
WAT
WAT
Annualised
WAT
21.0%
17.7%
CTKB

Income Statement — Q4 2025 vs Q4 2025

Metric
CTKB
CTKB
WAT
WAT
Revenue
$62.1M
$932.4M
Net Profit
$-44.1M
$225.2M
Gross Margin
52.9%
61.1%
Operating Margin
-9.0%
29.0%
Net Margin
-70.9%
24.2%
Revenue YoY
8.1%
6.8%
Net Profit YoY
-557.1%
-2.7%
EPS (diluted)
$3.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
WAT
WAT
Q4 25
$62.1M
$932.4M
Q3 25
$52.3M
$799.9M
Q2 25
$45.6M
$771.3M
Q1 25
$41.5M
$661.7M
Q4 24
$57.5M
$872.7M
Q3 24
$51.5M
$740.3M
Q2 24
$46.6M
$708.5M
Q1 24
$44.9M
$636.8M
Net Profit
CTKB
CTKB
WAT
WAT
Q4 25
$-44.1M
$225.2M
Q3 25
$-5.5M
$148.9M
Q2 25
$-5.6M
$147.1M
Q1 25
$-11.4M
$121.4M
Q4 24
$9.6M
$231.4M
Q3 24
$941.0K
$161.5M
Q2 24
$-10.4M
$142.7M
Q1 24
$-6.2M
$102.2M
Gross Margin
CTKB
CTKB
WAT
WAT
Q4 25
52.9%
61.1%
Q3 25
52.7%
59.0%
Q2 25
52.3%
58.3%
Q1 25
48.6%
58.2%
Q4 24
58.5%
60.1%
Q3 24
56.3%
59.3%
Q2 24
54.6%
59.3%
Q1 24
51.3%
58.9%
Operating Margin
CTKB
CTKB
WAT
WAT
Q4 25
-9.0%
29.0%
Q3 25
-17.6%
24.0%
Q2 25
-23.3%
24.4%
Q1 25
-36.1%
22.9%
Q4 24
5.2%
33.5%
Q3 24
-8.2%
28.5%
Q2 24
-18.3%
26.7%
Q1 24
-23.9%
21.0%
Net Margin
CTKB
CTKB
WAT
WAT
Q4 25
-70.9%
24.2%
Q3 25
-10.5%
18.6%
Q2 25
-12.2%
19.1%
Q1 25
-27.5%
18.3%
Q4 24
16.8%
26.5%
Q3 24
1.8%
21.8%
Q2 24
-22.4%
20.1%
Q1 24
-13.8%
16.0%
EPS (diluted)
CTKB
CTKB
WAT
WAT
Q4 25
$3.76
Q3 25
$2.50
Q2 25
$2.47
Q1 25
$2.03
Q4 24
$3.88
Q3 24
$2.71
Q2 24
$2.40
Q1 24
$1.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
WAT
WAT
Cash + ST InvestmentsLiquidity on hand
$90.9M
$587.8M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$341.7M
$2.6B
Total Assets
$461.5M
$5.1B
Debt / EquityLower = less leverage
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
WAT
WAT
Q4 25
$90.9M
$587.8M
Q3 25
$93.3M
$459.1M
Q2 25
$75.5M
$367.2M
Q1 25
$95.3M
$382.9M
Q4 24
$98.7M
$325.4M
Q3 24
$162.3M
$331.5M
Q2 24
$177.9M
$327.4M
Q1 24
$168.8M
$338.2M
Total Debt
CTKB
CTKB
WAT
WAT
Q4 25
$1.4B
Q3 25
Q2 25
Q1 25
Q4 24
$1.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CTKB
CTKB
WAT
WAT
Q4 25
$341.7M
$2.6B
Q3 25
$378.6M
$2.3B
Q2 25
$377.6M
$2.2B
Q1 25
$379.6M
$2.0B
Q4 24
$395.7M
$1.8B
Q3 24
$385.5M
$1.6B
Q2 24
$389.1M
$1.4B
Q1 24
$392.6M
$1.3B
Total Assets
CTKB
CTKB
WAT
WAT
Q4 25
$461.5M
$5.1B
Q3 25
$494.9M
$4.9B
Q2 25
$493.3M
$4.7B
Q1 25
$482.6M
$4.6B
Q4 24
$499.5M
$4.6B
Q3 24
$491.2M
$4.5B
Q2 24
$483.7M
$4.4B
Q1 24
$492.1M
$4.5B
Debt / Equity
CTKB
CTKB
WAT
WAT
Q4 25
0.55×
Q3 25
Q2 25
Q1 25
Q4 24
0.89×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
WAT
WAT
Operating Cash FlowLast quarter
$-771.0K
$164.6M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-2.9%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
0.73×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
WAT
WAT
Q4 25
$-771.0K
$164.6M
Q3 25
$-3.9M
$187.3M
Q2 25
$108.0K
$41.1M
Q1 25
$-125.0K
$259.6M
Q4 24
$2.0M
$240.1M
Q3 24
$13.2M
$204.6M
Q2 24
$6.2M
$54.5M
Q1 24
$4.0M
$262.9M
Free Cash Flow
CTKB
CTKB
WAT
WAT
Q4 25
$-1.8M
Q3 25
$-4.6M
Q2 25
$-1.5M
Q1 25
$-974.0K
Q4 24
$1.1M
Q3 24
$12.2M
Q2 24
$5.2M
Q1 24
$3.4M
FCF Margin
CTKB
CTKB
WAT
WAT
Q4 25
-2.9%
Q3 25
-8.7%
Q2 25
-3.2%
Q1 25
-2.3%
Q4 24
1.9%
Q3 24
23.7%
Q2 24
11.0%
Q1 24
7.6%
Capex Intensity
CTKB
CTKB
WAT
WAT
Q4 25
1.6%
Q3 25
1.3%
Q2 25
3.5%
Q1 25
2.0%
Q4 24
1.6%
Q3 24
2.0%
Q2 24
2.3%
Q1 24
1.3%
Cash Conversion
CTKB
CTKB
WAT
WAT
Q4 25
0.73×
Q3 25
1.26×
Q2 25
0.28×
Q1 25
2.14×
Q4 24
0.21×
1.04×
Q3 24
14.05×
1.27×
Q2 24
0.38×
Q1 24
2.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

WAT
WAT

Segment breakdown not available.

Related Comparisons